Navigation Links
Parker Waichman Alonso LLP, Along with Smith & Nevares, Salas & Co. and Becnel
Date:10/17/2007

in conventional pacemakers. Some patients with congestive heart failure use devices that include this defibrillation ability, and those are among the machines that use the Sprint Fidelis lead.

According to the lawsuit, the victim, a resident of Kentucky, received a cardiac pacemaker/defibrillator combination (an "ICD"). The ICD was attached to his heart with a Sprint Fidelis lead wire system manufactured by Medtronic on March 25, 2005. On June 22, 2006, the lead had to be surgically removed in an emergency procedure after it was found to be "frayed" in the nature of a fracture.

Those patients whose Sprint Fidelis lead fractures must undergo a dangerous surgical procedure to have the wire replaced. The procedure could cause tearing and scarring of the heart and veins through which the Sprint Fidelis lead wire runs. The surgery to replace a defibrillator lead wire is far riskier than having the device itself replaced.

Defibrillator leads are one of the devices most fragile components. Since the Sprint Fidelis lead was introduced to the market in 2004 it has become evident that a significant portion of the leads have potentially fatal defects. Such defects were discussed in an article written by doctors at The Minneapolis Heart Institute, one of the premier heart institutes in the world, based on a study of the incidence of lead failures in the Sprint Fidelis models compared to the Sprint Quattro models. Researchers at The Minneapolis Heart Institute found that, between September 2004 and February 2007, 583 patients were implanted with Sprint Fidelis Model 6949 leads and nine patients received other Sprint Fidelis models. During that time, six patients experienced Sprint Fidelis Model 6949 lead failures. The failed Sprint Fidelis Model 6949 leads had been implanted by various electrophysiologists, cardiologists and thoracic surgeons. The average time to failure was fourteen months (based on a range of four to twenty-three months). Medtronic first noti
'/>"/>

SOURCE Parker Waichman Alonso LLP
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Longoria and Parker Couples Not in a Hurry for Babies Now
2. ICMR along with other International Research organisation with drug development for Neglected Diseases
3. Help teenagers eat healthy by giving nutritional information along with food.
4. Boys Join the Race Along With Girl to Get a Stick like Figure
5. Grapefruit juice could be taken along with medication: the nutrient-drug reaction uncovered!
6. Yoga Along with Treatment for Breast Cancer Improves Quality of Life
7. Postmen to Deliver Anti-malaria Medicines Along with Letters in Jharkhand
8. FDA Approval for Lung Cancer Treatment -Avastin Along with Chemotherapy
9. Tooth Decay Bacteria Evolved Along With Man
10. Worlds Oldest High-wire Artiste Hums Along at 98
11. Red Cross Promotes Prevention, Control of TB Along U.S. - Mexican Border
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 2Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 3Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 4CVS Caremark Names New Chief Human Resources Officer 2Emerson Ecologics Introduces the Emerson Quality Partner 28TM 29 Program 55830 1Emerson Ecologics Introduces the Emerson Quality Partner 28TM 29 Program 55830 2Archi Tech Closes the Gap Between Pharmaceutical Managed Care and Primary Sales with Pull Through Reporting Capabilities 55826 1Archi Tech Closes the Gap Between Pharmaceutical Managed Care and Primary Sales with Pull Through Reporting Capabilities 55826 2NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 1NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 2NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 3NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 4NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 5